Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia?

European Respiratory Journal

Volumn 21, Issue 5, 2003, Pages 741-742

  Ewig, S ^a   Torres, A ^b  

^a Augusta Kranken Anstalt   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BRONCHOSCOPY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; COMMUNICABLE DISEASE; DIAGNOSTIC TEST; EDITORIAL; EMPIRICISM; HUMAN; IMMUNOFLUORESCENCE TEST; LUNG LAVAGE; MORTALITY; NONHUMAN; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; TREATMENT FAILURE;

CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL;

EID: 0038056342     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00023003     Document Type: Editorial

References (23)

1. Grayston JT, Kuo CC, Wang SP, Altmann J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161-168.
2. Blasi F, Consentini R, Legnani D, Denti F, Allegra L. Incidence of community acquired pneumonia caused by Chlamydia pneumoniae in Italian patients. Eur J Clin Microbiol Infect Dis 1993; 12: 696-699.
3. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543-547.
4. Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995; 152: 1309-1315.
5. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year propspective study of 346 consecutive patients. Thorax 1996; 51: 179-184.
6. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.
7. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405.
8. Park DR, Sherbin VL, Goodman MS, et al. for the Harborview CAP study. The etiology of community acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity. J Infect Dis 2001; 184: 268-277.
9. American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia.: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
10. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
11. Mandell LA, Marrie TJ, Grossmann RF, Chow AW, Hyland RH, and the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
12. Huchon G, Woodhead M. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-991.
13. BTS Guidelines for the management of community-acquired pneumonia. Thorax 2001; 56: Suppl. IV, 1-64.
14. Hammerschlag MR. Diagnostic methods for intracellular pathogens. Clin Microbiol Dis 1996; 1: Suppl. 1, S3-S9.
15. Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994; 32: 903-905.
16. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330-1335.
17. Shemer-Avni Y, Lieberman D. Chlamydia pneumoniae induced ciliostasis in ciliated human bronchial epithelial cells. J Infect Dis 1995; 171: 1274-1278.
18. Marrie TJ, Peeling RW, Reid T, De Carolis E, and the Canadian Community-Acquired Pneumonia Investigators: Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J 2003; 21: 779-784.
19. Menendez R, Cordoba J, Cuadra P, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999; 159: 1868-1873.
20. Dalhoff K, Maas M. Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in BAL. Chest 1996; 110: 351-356.
21. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42: 194-196.
22. Lieberman D, Ben-Yaakov M, Lanzarovich Z, et al. Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized patients. Infection 1995; 24: 109-114.
23. Marrie TJ, Grayston T, Wang S, Kuo C. Pneumonia associated with the TWAR strain of Chlamydia. Ann Intern Med 1987; 106: 507-511.